drugset / Trial / NCT06619678

A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

NCT06619678

Phase 1 Completed 36 enrolled Merck Sharp & Dohme LLC
NaSequentialOpen-labelTreatment

Summary

The main goals of this study are to learn what happens to Islatravir or MK-8507 in a person's body over time. Researchers will compare Islatravir given alone to Islatravir given with MK-8507. Researchers will also compare MK-8507 given alone to MK-8507 given with Islatravir.

Timeline

Start
2024-01-17
Primary completion
2024-06-23
Completion
2024-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Islatravir Other / unclassified Oral
Subject Ulonivirine Small molecule Oral

Indications

No indication recorded.